Teva files reply in support of dismissing US claims over Copaxone
MLex summary: Teva Pharmaceuticals filed a reply in support of its motion to dismiss third-party payors’ amended US antitrust claims accusing it of illegally delaying a generic competitor for multiple sclerosis...To view the full article, register now.
Already a subscriber? Click here to view full article